For NSCLC patients with wild-type EGFR, ALK, and ROS1 genes, the prevalence of BRAF V600E mutations is approximately 2.2–10.8% due to the mutually exclusive nature of these driver genes (21, 22). This evidence concerns the gene ALK and non-small cell lung carcinoma.